Rheumatology

Fresenius Kabi Maps Out Biosimilar Strategy

February 24th 2021

By Tony Hagen

The Germany-based company with global operations plans to ramp up its biosimilars portfolio through 2025.

Filling in the Blanks: The Patient-Provider Conversation About Biosimilars

February 22nd 2021

By Tony Hagen

Gary H. Lyman, MD, PhD, provides an expert overview on overcoming the challenges of discussing biosimilars with patients.

Not So Different: Sarfaraz Niazi, PhD Discusses Market Projections For High-Concentration Adalimumab Biosimilars

February 21st 2021

We sat down with Sarfaraz Niazi, PhD, an adjunct professor and biosimilar industry expert, to discuss the potential impact high-concentration adalimumab products could have on the US market.

Canada Sees Second Adalimumab Biosimilar Launch in a Week

February 19th 2021

By Tony Hagen

Fresenius Kabi steps into the Canadian market for adalimumab with Idacio.

Study: Increasing Biosimilar Use in RA Requires Greater Disease Management Knowledge

February 18th 2021

By Deana Ferreri, PhD

Biosimilar availability will expand treatment of rheumatoid arthritis (RA) to more patients and earlier disease settings, so it's important to understand the potential complications.

Coherus Files Adalimumab BLA, Although Intended Concentration Is Unclear

February 17th 2021

By Tony Hagen

Coherus BioSciences filed a 351(k) biologics license application (BLA) for CHS-1420, an adalimumab biosimilar candidate.

Sandoz Launches Adalimumab Biosimilar in Canada

February 16th 2021

By Tony Hagen

The launch of Hyrimoz gives Sandoz 5 biosimilars on the Canadian market. National policies on switching have given biosimilars a tailwind.

Celltrion Healthcare Gains EU Authorization for High-Concentration Adalimumab

February 15th 2021

By Tony Hagen

The marketing of Yuflyma is expected to give Celltrion Healthcare a significant advantage over existing adalimumab biosimilars.

Study: Gender, Internet Habits Influence Biosimilar Acceptance

February 15th 2021

By Tony Hagen

Patient characteristics are predictive of whether a switch to a biosimilar is likely to be accepted, investigators found.

Study: Nocebo Is Likely Cause for Reverse Switching in IBD

February 10th 2021

By Tony Hagen

Three-fourths of patients who reverse-switched to originator infliximab from CT-P13 benefited, although it wasn't clear why the biosimilar treatment "failed."